■ 刊行論文
|
原著
|
|
1.
|
Akamine H, Uzawa A, Kuwabara S, Suzuki S, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K.：
Predicting achievement of clinical goals using machine learning in myasthenia gravis.
PLoS One.
20
(8:e0330044.)
：
, 2025
|
|
2.
|
Konno S, Uzawa A, Samukawa M, Todaka H, Mishiro I, Taki K, Quelen C, Czubin A, Majewska R, Shiraiwa K, Ohashi Y：
Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study.
BMJ Open
15
(6:e095496.)
：
, 2025
|
|
3.
|
Samukawa M, Konno S†, Uzawa A, Taki K, Todaka H, Mishiro I, Quelen C, Łukowicz Z, Majewska R, Ohashi Y.：
Disease burden of myasthenia gravis in relation to oral corticosteroid dose: an insurance claims database study in Japan.
Front. Neurol. Front. Neurol.
16
(1662173)
：
, 2025
|
|
4.
|
Konno S. Uchi T, Kihara H, Fujioka T.：
5-Aminolevulinic acid ameliorates chronic experimental autoimmune neuritis through a dual mechanism of mitochondrial protection and immunomodulation.
Int. J. Mol. Sci.
26
(8512)
：
, 2025
|
|
5.
|
Uzawa A, Suzuki S, Kuwabara S, Yasuda M, Akamine H, Onishi Y, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K.：
Corticosteroid-induced Cushingoid Appearance in Myasthenia Gravis.
Intern Med.
Published online June 5, 2025. doi:10.2169/internalmedicine.5678-25
：
, 2025
|
|
6.
|
Akamine H, Uzawa A, Kuwabara S, Suzuki S, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K.：
Association between Myasthenia Gravis and Smoking.
Intern Med.
doi:10.2169/internalmedicine.
(5310-25)
：
, 2025
|
|
7.
|
Konno S, Uchi T, Kihara H, Sugimoto H.：
Functional Status Enhances the FRAX® Prediction of Fractures in Myasthenia Gravis: A 10-Year Cohort Study.
J Clin Med.
14
(9)
：3260
-3260
, 2025
|
|
総説及び解説
|
|
1.
|
紺野晋吾, 内孝文：
【神経免疫疾患で用いられる新しい分子標的薬】視神経脊髄炎スペクトラム障害,重症筋無力症,その他で用いられるリツキシマブ(解説).
脳神経内科
102
(6)
：621
-627
, 2025
|
|
